Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 18, 2016
- Accepted in final form October 10, 2016
- First Published December 5, 2016.
Author Disclosures
- Ramona Miske, PhD*,
- Catharina C. Gross, PhD*,
- Madeleine Scharf, PhD,
- Kristin S. Golombeck, MD,
- Marvin Hartwig,
- Urvashi Bhatia,
- Andreas Schulte-Mecklenbeck,
- Kathrin Bönte,
- Christine Strippel, MD,
- Ludger Schöls, MD,
- Matthis Synofzik, MD,
- Hubertus Lohmann, PhD,
- Inga Madeleine Dettmann, PhD,
- Michael Deppe, PhD,
- Swantje Mindorf,
- Tobias Warnecke, MD,
- Yvonne Denno,
- Bianca Teegen, PhD,
- Christian Probst, PhD,
- Stefanie Brakopp,
- Klaus-Peter Wandinger, MD,
- Heinz Wiendl, MD,
- Winfried Stöcker, MD,
- Sven G. Meuth, MD, PhD,
- Lars Komorowski, PhD‡ and
- Nico Melzer, MD‡
- Ramona Miske, PhD*,
NONE
NONE
NONE
NONE
Diagnostic test for the detction of autoantibodies against neurochondrin
NONE
EUROIMMUN AG, Postdoc, 4,5 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catharina C. Gross, PhD*,
NONE
NONE
I received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care.
Frontiers in Immunology, Review Editor, Since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG), GR3946/2-1, 01/2013- 12/2015 German Research Foundation (DFG), SFB-CRC-TR 129,Project A09 07/2016-06/2020 BMBF grant Disease-Related Competence Network Multiple Sclerosis, Immune MS, KKNMS-030
Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of M?nster, KL111421, 07/2014-06/2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Madeleine Scharf, PhD,
NONE
NONE
NONE
NONE
(1) Diagnostic test for the detection of autoantibodies against neurochondrin
NONE
(1) EUROIMMUN Medizinische Labordiagnostika AG, employee, 4 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kristin S. Golombeck, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Immunoabsorption (5%), 3 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marvin Hartwig,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Urvashi Bhatia,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreas Schulte-Mecklenbeck,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Bönte,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christine Strippel, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ludger Schöls, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I received the following grants: PI: Genetic disorders in Arab Societies (grant SCHO754/5-2), DFG: 2014-2016 PI: mitoMORPH (mitoNET, grant 01GM0864), BMBF: 2008-2014 PI: EUROSCAR (01GM1207) EU/BMBF: 2012-2015 PI: NEUROMICS (F5-2012-305121) EU: 2012-2017
NONE
I received additional funding from the HSP-Selbsthilfegruppe Deutschland eV and the F?rderverein fuer HSP-Forschung
NONE
NONE
NONE
NONE
NONE
NONE
- Matthis Synofzik, MD,
NONE
NONE
Actelion Pharmaceuticals, speakers honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Actelion Pharmaceuticals.
NONE
NONE
research grant by the Volkswagen Foundation, the Robert Bosch Stiftung, Ataxia UK, Katarina Witt Stiftung, Deutsche Heredit?re Ataxie Gesellschaft (DHAG), and Center for Rare Diseases T?bingen, Germany.
NONE
NONE
NONE
NONE
NONE
NONE
- Hubertus Lohmann, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Inga Madeleine Dettmann, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
by Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Deppe, PhD,
NONE
NONE
Travel and speaker honoraria from Sanofi Genzyme Corporation and Novartis Pharma GmbH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Swantje Mindorf,
NONE
NONE
NONE
NONE
NONE
NONE
Employed by EUROIMMUN
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Warnecke, MD,
NONE
NONE
(1)Abbvie, speaker honoraria (2)Teva, speaker honoraria (3)Bayer, speaker honoraria (4)Zamboon, speaker honoraria (5)UCB, speaker honoraria
NONE
NONE
NONE
NONE
(1) Abbvie, (2) UCB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yvonne Denno,
NONE
NONE
NONE
NONE
NONE
NONE
(1) EUROIMMUN AG, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bianca Teegen, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Probst, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun, full-time employee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun
NONE
NONE
NONE
NONE
NONE
- Stefanie Brakopp,
NONE
NONE
NONE
NONE
NONE
NONE
Employed by Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus-Peter Wandinger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Bayer Healthcare (2) Biogen Idec (3) Sanofi- Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva
NONE
(1) Bayer Vital GmbH (2) Bayer Schering AG (3) Biogen (4) CSL Behring (5) EMD Serono (6) Fresenius Medical Care (7) Sanofi - Genzyme (8) Merck Serono (9) Omniamed (10) Novartis (11) Teva (12) GlaxoSmithKline (13) GW Pharmaceuticals
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Biogen (2) Merck Serono (3) Novartis (4) Omniamed (5) Roche (6) Sanofi-Genzyme
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi ? Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2) European Union (EU), BD604219, principal investigator, 2013-2016 (3)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kr?ner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children?s Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Winfried Stöcker, MD,
NONE
NONE
NONE
NONE
(1) St?cker W. Verfahren und Vorrichtungen f?r Untersuchungen an unbeweglich gemachtem biologischem Material. Europ?ische Patentanmeldung 0 117 262 (1983). (2) St?cker W., Wandinger K., Komorowski L., Probst C. Verfahren zum Nachweis von Anti-NMDA-Rezeptor- Autoantik?rpern zum Einsatz in Diagnoseverfahren. Deutsche Patentanmeldung 10 2010 053 432.3 (2010), (3) St?cker W. Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antik?rpern. Deutsche Patentanmeldung 10 2011 011 280.4 (2011).
NONE
WS is a member of the Board of the Euroimmun AG. WS is a shareholder of the Euroimmun AG.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EUROIMMUN Medizinische Labordiagnostika AG
NONE
NONE
NONE
EUROIMMUN Medizinische Labordiagnostika AG
NONE
- Sven G. Meuth, MD, PhD,
(1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva
NONE
Sven G. Meuth (SGM) has received honoraria for lecturing and travel expenses from following commercial entities with no company exceeding 10,000 ?: (1)Almirall (2)Bayer Health Care (3)Biogen (4)Genzyme (5)Merck Serono (6)Novartis (7)Roche (8)TEVA
PLoS One
NONE
NONE
NONE
(1)Biogen (2)Genzyme (3)Merck Serono (4)Novartis (5)Roche (5)TEVA
NONE
NONE
NONE
(1)Bayer Health Care (2)Biogen (3)Genzyme (4)Merck Serono (5)Novartis (6)TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lars Komorowski, PhD‡ and
NONE
NONE
NONE
NONE
NONE
NONE
Employee of EUROIMMUN AG.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nico Melzer, MD‡
NONE
NONE
1. Biogen Idec, honoraria for lecturing and travel expenses for attending meetings 2. GlaxoSmith Kline, honoraria for lecturing and travel expenses for attending meetings 3. Teva, honoraria for lecturing and travel expenses for attending meetings 4. Fresenius Medical Care, honoraria for lecturing and travel expenses for attending meetings
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Immunoadsorption, (5%), 3 years
1. Fresenius Medical Care 2. Diamed
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Experimental Immunology (R.M., M. Scharf, I.M.D., S.M., Y.D., B.T., C.P., S.B., W.S., L.K.), Euroimmun AG, Lübeck; Department of Neurology (C.C.G., K.S.G., M.H., U.B., A.S.-M., K.B., C.S., H.L., M.D., T.W., H.W., S.G.M., N.M.), University of Münster; Centre for Neurology and Hertie-Institute for Clinical Brain Research (L.S., M. Synofzik), Tübingen; German Center for Neurodegenerative Diseases (DZNE) (L.S., M. Synofzik), Tübingen; and Institute of Clinical Chemistry and Department of Neurology (K.-P.W.), University Hospital of Schleswig-Holstein, Lübeck, Germany.
- Correspondence to Dr. Komorowski: l.komorowski{at}euroimmun.de or Dr. Melzer: nico.melzer{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.